Drug Fights GLP-1 Muscle Loss; Unapproved Retatrutide Prescriptions; Protein Swap

(MedPage Today) -- Investigational apitegromab -- a selective myostatin activation inhibitor -- effectively preserved lean mass when combined with tirzepatide (Zepbound) in a randomized phase II trial, suggesting it could help fight "Ozempic...
Source
MedPage Today
Opens original article in a new tab



